DexCom, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Steven Altman

DexCom, Inc.’s own tally for this item (“Elect Director: Steven Altman”): 299,051,663 for, 15,262,716 against, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Dexcom stockholders elected the following twelve nominees to the Company's board of directors, each to serve until Dexcom's 2027 annual meeting of stockholders or until their earlier death, resignation or removal, as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 174 asset managers below reported 140,947,648 for, 324,912 against, 13,793 abstained, 377 not voted.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

Description as filed by funds: To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Dr. Euan Ashley

The 174 asset managers below reported 141,142,616 for, 129,946 against, 13,793 abstained, 377 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

Description as filed by funds: To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Nicholas Augustinos

DexCom, Inc.’s own tally for this item (“Elect Director: Nicholas Augustinos”): 265,917,901 for, 47,957,634 against, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Dexcom stockholders elected the following twelve nominees to the Company's board of directors, each to serve until Dexcom's 2027 annual meeting of stockholders or until their earlier death, resignation or removal, as follows:”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 174 asset managers below reported 139,742,974 for, 1,529,584 against, 13,796 abstained, 377 not voted.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

Description as filed by funds: To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Richard Collins

The 174 asset managers below reported 141,044,432 for, 228,131 against, 13,793 abstained, 377 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

The 174 asset managers below reported 141,232,941 for, 29,621 against, 13,793 abstained, 377 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

Description as filed by funds: To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Mark Foletta

DexCom, Inc.’s own tally for this item (“Elect Director: Mark Foletta”): 308,685,713 for, 5,641,368 against, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Dexcom stockholders elected the following twelve nominees to the Company's board of directors, each to serve until Dexcom's 2027 annual meeting of stockholders or until their earlier death, resignation or removal, as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 174 asset managers below reported 141,109,542 for, 126,421 against, 13,793 abstained, 377 not voted.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

Description as filed by funds: To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Bridgette Heller

The 174 asset managers below reported 141,165,544 for, 70,418 against, 13,793 abstained, 377 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

Description as filed by funds: To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Kyle Malady

DexCom, Inc.’s own tally for this item (“Elect Director: Kyle Malady”): 313,438,268 for, 885,232 against, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Dexcom stockholders elected the following twelve nominees to the Company's board of directors, each to serve until Dexcom's 2027 annual meeting of stockholders or until their earlier death, resignation or removal, as follows:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 174 asset managers below reported 141,206,338 for, 29,625 against, 13,793 abstained, 377 not voted.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

Description as filed by funds: To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Rick Osterloh

DexCom, Inc.’s own tally for this item (“Elect Director: Rick Osterloh”): 312,967,950 for, 1,356,590 against, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Dexcom stockholders elected the following twelve nominees to the Company's board of directors, each to serve until Dexcom's 2027 annual meeting of stockholders or until their earlier death, resignation or removal, as follows:”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 174 asset managers below reported 141,206,335 for, 29,627 against, 13,793 abstained, 377 not voted.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

Description as filed by funds: To elect twelve nominees for director, each to hold office until our 2027 annual meeting of stockholders: Kevin Sayer

DexCom, Inc.’s own tally for this item (“Elect Director: Kevin Sayer”): 307,497,531 for, 6,831,418 against, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Dexcom stockholders elected the following twelve nominees to the Company's board of directors, each to serve until Dexcom's 2027 annual meeting of stockholders or until their earlier death, resignation or removal, as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 174 asset managers below reported 140,980,487 for, 255,476 against, 13,793 abstained, 377 not voted.

Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.

The 173 asset managers below reported 141,106,064 for, 29,662 against, 13,793 abstained, 377 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 173 asset managers. See all 173 in the interactive database.

The 168 asset managers below reported 140,591,513 for, 29,622 against, 13,793 abstained, 377 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 168 asset managers. See all 168 in the interactive database.

Description as filed by funds: To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025.

DexCom, Inc.’s own tally for this item (“3. Advisory Vote to Approve Named Executive Officer Compensation”): 277,111,475 for, 36,664,959 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Dexcom stockholders approved, on a non-binding advisory basis, the compensation of Dexcom's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K in the proxy statement for the Annual Meeting (which disclosure includes the Compensation Discussion and Analysis, the compensati…”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 171 managers: 139,123,238 for, 1,941,767 against, 23,980 abstained, 377 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 722 managers: 170,924,808 for, 30,246,068 against, 471,118 abstained, 67,024 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

DexCom, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 336,046,596 for, 373,544 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Dexcom stockholders ratified the selection by the audit committee of the board of directors of Deloitte & Touche LLP as Dexcom's independent registered public accounting firm for the fiscal year ending December 31, 2026, as follows:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of DexCom, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (3 managers, 120,130 for).

The 168 asset managers below reported 140,833,588 for, 13,793 abstained, 377 not voted.

Showing the 25 largest of 168 asset managers. See all 168 in the interactive database.